- Sections
- A - Nécessités courantes de la vie
- A61K - Préparations à usage médical, dentaire ou pour la toilette
- A61K 39/108 - EscherichiaKlebsiella
Détention brevets de la classe A61K 39/108
Brevets de cette classe: 638
Historique des publications depuis 10 ans
58
|
50
|
39
|
44
|
48
|
55
|
48
|
39
|
52
|
21
|
2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
Propriétaires principaux
Proprétaire |
Total
|
Cette classe
|
---|---|---|
Glaxosmithkline Biologicals S.A. | 1636 |
50 |
Janssen Pharmaceuticals, Inc. | 428 |
42 |
Pfizer Inc. | 3367 |
15 |
Qu Biologics Inc. | 31 |
15 |
Zoetis Services LLC | 1540 |
15 |
Cornell University | 3284 |
14 |
University of Maryland, Baltimore | 1008 |
14 |
Sequoia Vaccines, Inc. | 14 |
12 |
The United States of America as represented by the Secretary of the Navy | 2735 |
11 |
Scandinavian Biopharma Holding AB | 18 |
10 |
Northwestern University | 3364 |
8 |
Board of Trustees of the University of Arkansas | 806 |
6 |
The Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc. | 364 |
6 |
Vaxxinova US, Inc. | 50 |
6 |
Idemitsu Kosan Co., Ltd. | 4152 |
5 |
The Board of Trustees of the University of Illinois | 2683 |
5 |
University of Southern California | 2104 |
5 |
The Administrators of the Tulane Educational Fund | 392 |
5 |
South Dakota State University | 73 |
5 |
The Texas a & M University System | 1679 |
5 |
Autres propriétaires | 384 |